Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer

NCT06951399 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)
NSCLC Stage IV Without EGFR/ALK Mutation
NSCLC Adenocarcinoma

Interventions

DRUG: Pembrolizumab (KEYTRUDA®)

Sponsor

Rabin Medical Center

Collaborators

[object Object]